Published in Oncotarget on December 29, 2015
REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer. Sci Rep (2017) 0.75
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. J Cancer (2017) 0.75
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res (1997) 3.67
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate (2008) 1.86
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol (2012) 1.68
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2013) 1.58
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Fyn: a novel molecular target in cancer. Cancer (2010) 1.40
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
FYN is overexpressed in human prostate cancer. BJU Int (2008) 1.22
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol (2007) 1.13
Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer (2009) 1.02
Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review. Prostate Cancer Prostatic Dis (2014) 0.99
Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. Asian J Androl (2014) 0.97
Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate (2013) 0.94
Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest (1998) 0.93
Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate (2006) 0.93
Neuroendocrine differentiation of prostate cancer. Asian J Androl (2013) 0.93
Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One (2013) 0.91
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. Brain Res (2011) 0.91
Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Prostate (2007) 0.89
Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells. Br J Cancer (2005) 0.88
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol (2013) 0.87
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res (2011) 0.87
The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice. Prostate (2009) 0.82